53476-71-4

Usage

InChI:InChI=1/C9H12N2O2/c12-8-6-4-2-1-3-5-7(6)10-9(13)11-8/h1-5H2,(H2,10,11,12,13)

Upstream product

• 502-42-1 cycloheptanone 
• 52784-32-4 2-(methoxycarbonyl)cycloheptanone 
• 162397-32-2 methyl 2-amino-1-cycloheptene-1-carboxylate 
• 774-05-0 ethyl cycloheptanone-2-carboxylate 
• 57-13-6 urea 
• 179806-27-0 2,4-Bis-methanesulfonyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine 

Downstream Products

• 76780-96-6 2,4-dichloro-5,6-pentamethylenepyrimidine 

Relevant academic research and scientific papers

Synthetic method of medical intermediate cycloalkanopyrimidinedione compound

The invention provides a synthetic method of a cycloalkanopyrimidinedione compound, and belongs to the technical field of organic synthesis. The method provided by the invention comprises the following steps of: taking a 2-methoxycarbonyl naphthenone comp

Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer

Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) were discussed in detailed. Among the screened compounds, derivative 35 showed excellent enzymatic inhibitory activity (IC50, 36 nM). The cellular inhibition results showed that compound 35 had good antiproliferative activity against the non-small cell lung cancer A549 cells (IC50, 1.61 μM). Liver microsome stability showed that the half-life of compound 35 in human liver microsome was 42.3 min, which was more stable than the control CB-5083 (25.8 min). The in vivo pharmacokinetic results showed that the elimination phase half-lives of compound 35 were 4.57 h for ig and 3.64 h for iv, respectively and the oral bioavailability was only 4.5%. These results indicated that compound 35 could be effective for intravenous treatment of non-small cell lung cancer.

New procedures for the synthesis of heterocyclic substituted and 2,4-difunctionalized pyrimidines

N-Tosyl-2-and -3-acetylpyrrols 1 or N-tosyl-2-pyrrolidone 5 were condensed with cyano compounds in the presence of triflic anhydride (Tf2O) to yield heteroarylpyrimidines. 2,4-Difunctionalized pyrimidines were obtained by reaction of the corresponding 2,4-bis(methylsulfonyl)pyrimidines with nucleophiles.

Pyrimidine derivatives I. Synthesis of hypoglycemic 2-piperazino-5,6-polymethylenepyrimidines 5,6-polymethylenepyrimidines

Synthesis and hypoglycemic activity of 36 novel 2,4-diamino-5,6-polymethylenepyrimidine derivatives are described. Derivatives containing piperazino groups at position 2 showed a potent hypoglycemic activity and concomitantly inhibited platelet aggregation.